论文部分内容阅读
目的 探讨阻断乙型肝炎病毒母婴垂直传播的方法。方法 将 4 88例HBsAg阳性孕妇分成四组 ,单纯HBVac治疗组 116例 ,单纯HBIG治疗组 116例 ,左旋咪唑涂布剂加两者联合应用 12 0例 ,未治疗组 136例。治疗组均在孕 2 6周起开始注射 ,孕妇和新生儿血清HBsAg、抗 -HBs、HBeAg、抗 -HBe、抗 -HBc检测采用ELISA法。随访产妇及新生儿的乙肝标志物(HBVM)变化。结果 脐血中HBsAg阳性率 :HBVaC治疗组为 18.10 % ,HBIG治疗组为 9% ,联合治疗组为 3.33% ,未治疗组为2 4 .2 6 %。随访母亲HBVM多数转为HBSAg、抗 -HBC、抗 -HBc阳性 ,所生儿童抗 -HBs>70 %。结论 携带HBV孕妇于孕晚期给予HBVac、HBIG和左旋咪唑涂布剂联合两者治疗后 ,可有效阻断HBV母婴之间传播。
Objective To explore ways to block the vertical transmission of hepatitis B virus Methods Four hundred and seventy-eight HBsAg positive pregnant women were divided into four groups: 116 patients in the simple HBVac group, 116 patients in the HBIG-treated group alone, and 124 patients in the untreated group. The treatment group started injection at 26 weeks of pregnancy. The serum HBsAg, anti-HBs, HBeAg, anti-HBe and anti-HBc in pregnant women and newborns were detected by ELISA. Follow-up changes of HBVM in maternal and newborn. Results The positive rate of HBsAg in cord blood was 18.10% in HBVaC treated group, 9% in HBIG treated group, 3.33% in combined treatment group and 24.26% in untreated group. The majority of mothers followed HBMSAg, anti-HBC, anti-HBc positive, and anti-HBs in their children> 70%. Conclusion The HBV carriers carrying HBsAg, HBIG and levamisole in the third trimester of pregnancy can effectively block the transmission of HBV between mother and child.